Assessment of Anti- HCV Chemotherapy among Egyptian Patients

Egypt is one of the largest epidemic areas of hepatitis C virus (HCV) in the world. Its prevalent genotype is 4 with a majority of subtype 4a. In 2013, the Food and Drug Administration approved a new direct-acting antiviral drug (sofosbuvir) to treat patients with chronic HCV infection. In Egypt, the patients are already being treated with sofosbuvir in conjunction with ribavirin and pegylated interferon alfa-2a (PEG-IFNα-2a) for 12 weeks since 2015. The present study was planned to explain the efficacy of this treatment regimen against the HCV genotype 4a in Egyptian patients. In this population-based study, serum samples were biochemically analyzed, and the HCV RNA levels were quantified. The sustained virological response (SVR) was achieved following the treatment regimen. The multivariable analysis recognized viral level of viremia and alanine aminotransferase and aspartate aminotransferase levels affecting the virological response in patients infected with high viral load of HCV. Finally, these results concluded that sofosbuvir with ribavirin are highly efficient in HCV Egyptian patients where a high SVR was achieved.